Randomized Phase II Study Comparing Gemcitabine/S-1 Combination Chemoradiotherapy With Gemcitabine/S-1 Combination Chemotherapy for Unresectable Locally Advanced Pancreatic Cancer.

NCT01430052 Phase 2 COMPLETED

The purpose of this study is to evaluate the clinical effectiveness of Gemcitabine/S-1 combination chemoradiotherapy with Gemcitabine /S-1 combination chemotherapy for unresectable locally advanced pancreatic cancer.

Details

Lead sponsor	Osaka Medical Center for Cancer and Cardiovascular Diseases
Phase	Phase 2
Status	COMPLETED
Enrolment	110
Start date	2009-04
Completion	2015-09

Conditions

• Pancreatic Cancer

Interventions

• Drug: gemcitabine, S-1
• gemcitabine, S-1, radiotherapy

Primary outcomes

• Two year survival rate — 2 years

Countries

Japan